Specifically, antibodies for blocking the interaction between programmed death-ligand 1 (PD-L1) and its receptor, PD-1, have been developed, enhancing treatment outcomes in non-small cell lung cancer (NSCLC), urothelial bladder cancer, and triple-negative breast cancer (TNBC) [3–5]. Here, CD274 is linked to non-small cell lung carcinoma.